Bordetella pertussis infection following relaxation of COVID-19 non-pharmaceutical interventions in 2021–2023 in Vancouver metropolitan area, British Columbia, Canada
We recently reported a near disappearance of B. pertussis and a decline in anti-B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021–2023, incidence of reported B. pe...
Saved in:
| Published in | Vaccine Vol. 42; no. 22; p. 126004 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
17.09.2024
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2024.05.052 |
Cover
| Abstract | We recently reported a near disappearance of B. pertussis and a decline in anti-B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021–2023, incidence of reported B. pertussis cases remained low in BC at < 1/100,000 population. This study determined how serological evidence of B. pertussis changed after the gradual relaxation of NPI between 2021–2023.
Randomly selected blood samples from school staff 25–51 years old (n = 65) were collected yearly between 2021–2023 in the Vancouver metropolitan area, BC, Canada, and tested for anti-pertussis toxin (PT) IgG levels. Serological evidence of B. pertussis infection (thereafter “seroconversion”) was defined as a quantifiable anti-PT IgG levels in subjects with anti-PT IgG levels below lower limit of quantification in the preceding year or a > 4-fold increase in anti-PT IgG levels between two subsequent years. Samples were also tested for anti-diphtheria toxoid (DT) IgG, and similar seroconversion criteria were applied to exclude seroconversion due to vaccination with tetanus-diphtheria-acellular-pertussis (Tdap).
Three subjects met seroconversion criteria for anti-PT IgG between 2021 and 2022 and 9 between 2022 and 2023, yielding a seroconversion rate of 4.6 /100 person-years and 14.9/100 person-years, P = 0.127, respectively. None of the subjects met the criteria for vaccination with Tdap. The geometric mean concentration of anti-PT IgG showed a statistically significant decrease in 2022 compared with 2021, 4.8 IU/mL IU/ml (95 % confidence interval [CI], 3.8–5.9) vs. 6.4 IU/ml (95 % CI, 4.9–8.2; p = 0.001), followed by a statistically significant increase in 2023 compared with 2022 6.5 IU/ml (95 % CI, 4.9–8.5) vs. 4.8 IU/ml (95 % CI, 3.8–5.9; p = 0.0006), respectively.
Serological evidence of B. pertussis increased between 2022 and 2023 despite low reported cases, which suggests that B. pertussis circulation resumed after relaxing of COVID-19 NPI. |
|---|---|
| AbstractList | Background We recently reported a near disappearance of B. pertussis and a decline in anti- B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021–2023, incidence of reported B. pertussis cases remained low in BC at < 1/100,000 population. This study determined how serological evidence of B. pertussis changed after the gradual relaxation of NPI between 2021–2023. Methods Randomly selected blood samples from school staff 25–51 years old (n = 65) were collected yearly between 2021–2023 in the Vancouver metropolitan area, BC, Canada, and tested for anti-pertussis toxin (PT) IgG levels. Serological evidence of B. pertussis infection (thereafter “seroconversion”) was defined as a quantifiable anti-PT IgG levels in subjects with anti-PT IgG levels below lower limit of quantification in the preceding year or a > 4-fold increase in anti-PT IgG levels between two subsequent years. Samples were also tested for anti-diphtheria toxoid (DT) IgG, and similar seroconversion criteria were applied to exclude seroconversion due to vaccination with tetanus-diphtheria-acellular-pertussis (Tdap). Results Three subjects met seroconversion criteria for anti-PT IgG between 2021 and 2022 and 9 between 2022 and 2023, yielding a seroconversion rate of 4.6 /100 person-years and 14.9/100 person-years, P = 0.127, respectively. None of the subjects met the criteria for vaccination with Tdap. The geometric mean concentration of anti-PT IgG showed a statistically significant decrease in 2022 compared with 2021, 4.8 IU/mL IU/ml (95 % confidence interval [CI], 3.8–5.9) vs. 6.4 IU/ml (95 % CI, 4.9–8.2; p = 0.001), followed by a statistically significant increase in 2023 compared with 2022 6.5 IU/ml (95 % CI, 4.9–8.5) vs. 4.8 IU/ml (95 % CI, 3.8–5.9; p = 0.0006), respectively. Discussion Serological evidence of B. pertussis increased between 2022 and 2023 despite low reported cases, which suggests that B. pertussis circulation resumed after relaxing of COVID-19 NPI. We recently reported a near disappearance of B. pertussis and a decline in anti-B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021-2023, incidence of reported B. pertussis cases remained low in BC at < 1/100,000 population. This study determined how serological evidence of B. pertussis changed after the gradual relaxation of NPI between 2021-2023.BACKGROUNDWe recently reported a near disappearance of B. pertussis and a decline in anti-B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021-2023, incidence of reported B. pertussis cases remained low in BC at < 1/100,000 population. This study determined how serological evidence of B. pertussis changed after the gradual relaxation of NPI between 2021-2023.Randomly selected blood samples from school staff 25-51 years old (n = 65) were collected yearly between 2021-2023 in the Vancouver metropolitan area, BC, Canada, and tested for anti-pertussis toxin (PT) IgG levels. Serological evidence of B. pertussis infection (thereafter "seroconversion") was defined as a quantifiable anti-PT IgG levels in subjects with anti-PT IgG levels below lower limit of quantification in the preceding year or a > 4-fold increase in anti-PT IgG levels between two subsequent years. Samples were also tested for anti-diphtheria toxoid (DT) IgG, and similar seroconversion criteria were applied to exclude seroconversion due to vaccination with tetanus-diphtheria-acellular-pertussis (Tdap).METHODSRandomly selected blood samples from school staff 25-51 years old (n = 65) were collected yearly between 2021-2023 in the Vancouver metropolitan area, BC, Canada, and tested for anti-pertussis toxin (PT) IgG levels. Serological evidence of B. pertussis infection (thereafter "seroconversion") was defined as a quantifiable anti-PT IgG levels in subjects with anti-PT IgG levels below lower limit of quantification in the preceding year or a > 4-fold increase in anti-PT IgG levels between two subsequent years. Samples were also tested for anti-diphtheria toxoid (DT) IgG, and similar seroconversion criteria were applied to exclude seroconversion due to vaccination with tetanus-diphtheria-acellular-pertussis (Tdap).Three subjects met seroconversion criteria for anti-PT IgG between 2021 and 2022 and 9 between 2022 and 2023, yielding a seroconversion rate of 4.6 /100 person-years and 14.9/100 person-years, P = 0.127, respectively. None of the subjects met the criteria for vaccination with Tdap. The geometric mean concentration of anti-PT IgG showed a statistically significant decrease in 2022 compared with 2021, 4.8 IU/mL IU/ml (95 % confidence interval [CI], 3.8-5.9) vs. 6.4 IU/ml (95 % CI, 4.9-8.2; p = 0.001), followed by a statistically significant increase in 2023 compared with 2022 6.5 IU/ml (95 % CI, 4.9-8.5) vs. 4.8 IU/ml (95 % CI, 3.8-5.9; p = 0.0006), respectively.RESULTSThree subjects met seroconversion criteria for anti-PT IgG between 2021 and 2022 and 9 between 2022 and 2023, yielding a seroconversion rate of 4.6 /100 person-years and 14.9/100 person-years, P = 0.127, respectively. None of the subjects met the criteria for vaccination with Tdap. The geometric mean concentration of anti-PT IgG showed a statistically significant decrease in 2022 compared with 2021, 4.8 IU/mL IU/ml (95 % confidence interval [CI], 3.8-5.9) vs. 6.4 IU/ml (95 % CI, 4.9-8.2; p = 0.001), followed by a statistically significant increase in 2023 compared with 2022 6.5 IU/ml (95 % CI, 4.9-8.5) vs. 4.8 IU/ml (95 % CI, 3.8-5.9; p = 0.0006), respectively.Serological evidence of B. pertussis increased between 2022 and 2023 despite low reported cases, which suggests that B. pertussis circulation resumed after relaxing of COVID-19 NPI.DISCUSSIONSerological evidence of B. pertussis increased between 2022 and 2023 despite low reported cases, which suggests that B. pertussis circulation resumed after relaxing of COVID-19 NPI. We recently reported a near disappearance of B. pertussis and a decline in anti-B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021–2023, incidence of reported B. pertussis cases remained low in BC at < 1/100,000 population. This study determined how serological evidence of B. pertussis changed after the gradual relaxation of NPI between 2021–2023. Randomly selected blood samples from school staff 25–51 years old (n = 65) were collected yearly between 2021–2023 in the Vancouver metropolitan area, BC, Canada, and tested for anti-pertussis toxin (PT) IgG levels. Serological evidence of B. pertussis infection (thereafter “seroconversion”) was defined as a quantifiable anti-PT IgG levels in subjects with anti-PT IgG levels below lower limit of quantification in the preceding year or a > 4-fold increase in anti-PT IgG levels between two subsequent years. Samples were also tested for anti-diphtheria toxoid (DT) IgG, and similar seroconversion criteria were applied to exclude seroconversion due to vaccination with tetanus-diphtheria-acellular-pertussis (Tdap). Three subjects met seroconversion criteria for anti-PT IgG between 2021 and 2022 and 9 between 2022 and 2023, yielding a seroconversion rate of 4.6 /100 person-years and 14.9/100 person-years, P = 0.127, respectively. None of the subjects met the criteria for vaccination with Tdap. The geometric mean concentration of anti-PT IgG showed a statistically significant decrease in 2022 compared with 2021, 4.8 IU/mL IU/ml (95 % confidence interval [CI], 3.8–5.9) vs. 6.4 IU/ml (95 % CI, 4.9–8.2; p = 0.001), followed by a statistically significant increase in 2023 compared with 2022 6.5 IU/ml (95 % CI, 4.9–8.5) vs. 4.8 IU/ml (95 % CI, 3.8–5.9; p = 0.0006), respectively. Serological evidence of B. pertussis increased between 2022 and 2023 despite low reported cases, which suggests that B. pertussis circulation resumed after relaxing of COVID-19 NPI. We recently reported a near disappearance of B. pertussis and a decline in anti-B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021–2023, incidence of reported B. pertussis cases remained low in BC at < 1/100,000 population. This study determined how serological evidence of B. pertussis changed after the gradual relaxation of NPI between 2021–2023. Randomly selected blood samples from school staff 25–51 years old (n = 65) were collected yearly between 2021–2023 in the Vancouver metropolitan area, BC, Canada, and tested for anti-pertussis toxin (PT) IgG levels. Serological evidence of B. pertussis infection (thereafter “seroconversion”) was defined as a quantifiable anti-PT IgG levels in subjects with anti-PT IgG levels below lower limit of quantification in the preceding year or a > 4-fold increase in anti-PT IgG levels between two subsequent years. Samples were also tested for anti-diphtheria toxoid (DT) IgG, and similar seroconversion criteria were applied to exclude seroconversion due to vaccination with tetanus-diphtheria-acellular-pertussis (Tdap). Three subjects met seroconversion criteria for anti-PT IgG between 2021 and 2022 and 9 between 2022 and 2023, yielding a seroconversion rate of 4.6 /100 person-years and 14.9/100 person-years, P = 0.127, respectively. None of the subjects met the criteria for vaccination with Tdap. The geometric mean concentration of anti-PT IgG showed a statistically significant decrease in 2022 compared with 2021, 4.8 IU/mL IU/ml (95 % confidence interval [CI], 3.8–5.9) vs. 6.4 IU/ml (95 % CI, 4.9–8.2; p = 0.001), followed by a statistically significant increase in 2023 compared with 2022 6.5 IU/ml (95 % CI, 4.9–8.5) vs. 4.8 IU/ml (95 % CI, 3.8–5.9; p = 0.0006), respectively. Serological evidence of B. pertussis increased between 2022 and 2023 despite low reported cases, which suggests that B. pertussis circulation resumed after relaxing of COVID-19 NPI. AbstractBackgroundWe recently reported a near disappearance of B. pertussis and a decline in anti- B. pertussis antibodies during the peak implementation of Coronavirus disease 2019 (COVID-19) non-pharmaceutical interventions (NPI) in 2021 in British Columbia (BC), Canada. During 2021–2023, incidence of reported B. pertussis cases remained low in BC at < 1/100,000 population. This study determined how serological evidence of B. pertussis changed after the gradual relaxation of NPI between 2021–2023. MethodsRandomly selected blood samples from school staff 25–51 years old (n = 65) were collected yearly between 2021–2023 in the Vancouver metropolitan area, BC, Canada, and tested for anti-pertussis toxin (PT) IgG levels. Serological evidence of B. pertussis infection (thereafter “seroconversion”) was defined as a quantifiable anti-PT IgG levels in subjects with anti-PT IgG levels below lower limit of quantification in the preceding year or a > 4-fold increase in anti-PT IgG levels between two subsequent years. Samples were also tested for anti-diphtheria toxoid (DT) IgG, and similar seroconversion criteria were applied to exclude seroconversion due to vaccination with tetanus-diphtheria-acellular-pertussis (Tdap). ResultsThree subjects met seroconversion criteria for anti-PT IgG between 2021 and 2022 and 9 between 2022 and 2023, yielding a seroconversion rate of 4.6 /100 person-years and 14.9/100 person-years, P = 0.127, respectively. None of the subjects met the criteria for vaccination with Tdap. The geometric mean concentration of anti-PT IgG showed a statistically significant decrease in 2022 compared with 2021, 4.8 IU/mL IU/ml (95 % confidence interval [CI], 3.8–5.9) vs. 6.4 IU/ml (95 % CI, 4.9–8.2; p = 0.001), followed by a statistically significant increase in 2023 compared with 2022 6.5 IU/ml (95 % CI, 4.9–8.5) vs. 4.8 IU/ml (95 % CI, 3.8–5.9; p = 0.0006), respectively. DiscussionSerological evidence of B. pertussis increased between 2022 and 2023 despite low reported cases, which suggests that B. pertussis circulation resumed after relaxing of COVID-19 NPI. |
| ArticleNumber | 126004 |
| Author | Abu-Raya, Bahaa Reicherz, Frederic Li, Sirui Watts, Allison A. Lavoie, Pascal M. Goldfarb, David M. |
| Author_xml | – sequence: 1 givenname: Frederic surname: Reicherz fullname: Reicherz, Frederic organization: BC Children's Hospital Research Institute, Vancouver, Canada – sequence: 2 givenname: Sirui surname: Li fullname: Li, Sirui organization: BC Children's Hospital Research Institute, Vancouver, Canada – sequence: 3 givenname: Allison A. orcidid: 0000-0001-7874-7030 surname: Watts fullname: Watts, Allison A. organization: BC Children's Hospital Research Institute, Vancouver, Canada – sequence: 4 givenname: David M. orcidid: 0000-0003-0835-9504 surname: Goldfarb fullname: Goldfarb, David M. organization: BC Children's Hospital Research Institute, Vancouver, Canada – sequence: 5 givenname: Pascal M. orcidid: 0000-0002-2205-0362 surname: Lavoie fullname: Lavoie, Pascal M. organization: BC Children's Hospital Research Institute, Vancouver, Canada – sequence: 6 givenname: Bahaa surname: Abu-Raya fullname: Abu-Raya, Bahaa email: Bahaa.AbuRaya@Dal.ca organization: Department of Pediatrics, University of British Columbia, Vancouver, Canada |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38797627$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkstu1DAUhi1URKcDjwCyxIYFGWwnjp0FIBpulSp1AVTsLMc5oR4Se7CTge54B16C5-JJcJihi0qoSJaObH3n97n8R-jAeQcI3adkRQktn6xXW22MdbBihBUrwtNht9CCSpFnjFN5gBaElUVWUPLxEB3FuCaE8JxWd9BhLkUlSiYW6OexDy2M0PcabyCMU4w2Yus6MKP1Dne-7_1X6z7hAL3-pv88-g7XZ-cnLzNa4VRWtrnQYdAGptEa3afsEcIW3MzOWjhVSH99_5FCPl_PtTN-2kLAA4zBb3xvR-2wDqAf4-NgRxsvcO37aWhseqm1062-i253uo9wbx-X6MPrV-_rt9np2ZuT-sVpZgqZj5kBSbhsRMe6smsYl4zyttNtUYqilC1njOnGSNnkaYhVVZjWcNPKIqGEC0rzJXq0090E_2WCOKrBRjPPx4Gfosopz4VgTFQ3o6QkgjOS2l6ih9fQtZ-CS40kqqqYkELMfz_YU1MzQKs2wQ46XKq_60oA3wEm-BgDdFcIJWq2hVqrvS3UbAtFeDrz9893eZAmt7UQVDQWnIHWhrRo1Xp7o8Kzawqmt25e92e4hHjVDVWRKaLezdabnccKQso0giTw9N8C_1HAb0EY7OE |
| Cites_doi | 10.1186/s12916-015-0382-8 10.1186/s12889-022-12830-9 10.1086/504803 10.1093/cid/ciz531 10.1136/bmjopen-2021-057846 10.1016/j.vaccine.2022.04.086 10.1080/21645515.2020.1844505 10.1016/j.vaccine.2022.10.020 10.1038/s41541-020-00270-8 10.1007/s40121-021-00440-8 10.1086/313913 10.3346/jkms.2018.33.e321 10.2807/1560-7917.ES.2021.26.29.2100639 10.1542/peds.2015-3326 10.1093/infdis/jiac192 10.3390/vaccines10060872 10.1093/jpids/piy128 10.1002/jmv.26614 10.1111/apm.13165 10.1007/s10096-001-0639-3 10.2217/fmb.09.133 10.1136/bmjopen-2022-071228 10.1007/s10096-010-1104-y 10.4161/hv.36167 10.1093/cid/cix691 10.1056/NEJMcp041025 10.1093/cid/cis287 10.1093/cid/ciaa1682 10.1007/s40121-023-00895-x 10.1073/pnas.1314688110 |
| ContentType | Journal Article |
| Copyright | 2025 The Authors The Authors Copyright © 2024 Elsevier Ltd. All rights reserved. 2025. The Authors |
| Copyright_xml | – notice: 2025 The Authors – notice: The Authors – notice: Copyright © 2024 Elsevier Ltd. All rights reserved. – notice: 2025. The Authors |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2024.05.052 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection (ProQuest) Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Research Library Prep MEDLINE - Academic AGRICOLA MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 126004 |
| ExternalDocumentID | 38797627 10_1016_j_vaccine_2024_05_052 S0264410X24006200 1_s2_0_S0264410X24006200 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | British Columbia British Columbia Canada Canada Germany |
| GeographicLocations_xml | – name: British Columbia – name: British Columbia Canada – name: Canada – name: Germany |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SEW SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SIN SVS WUQ XPP ZGI ZXP 6I. AAFTH AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP CITATION CGR CUY CVF ECM EFLBG EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c483t-ce8058b7f2f6fb258215dfad467468d5222abc88b3016994cdc5cd84b25057113 |
| IEDL.DBID | AIKHN |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Fri Sep 05 17:23:19 EDT 2025 Fri Sep 05 09:04:37 EDT 2025 Wed Aug 13 06:59:25 EDT 2025 Thu Sep 04 04:46:18 EDT 2025 Tue Jul 01 01:07:19 EDT 2025 Sat Feb 01 16:09:12 EST 2025 Mon Feb 24 20:16:08 EST 2025 Tue Aug 26 19:55:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 22 |
| Language | English |
| License | This is an open access article under the CC BY-NC license. Copyright © 2024 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c483t-ce8058b7f2f6fb258215dfad467468d5222abc88b3016994cdc5cd84b25057113 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-0835-9504 0000-0002-2205-0362 0000-0001-7874-7030 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0264410X24006200 |
| PMID | 38797627 |
| PQID | 3099278771 |
| PQPubID | 105530 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_3153772279 proquest_miscellaneous_3060752002 proquest_journals_3099278771 pubmed_primary_38797627 crossref_primary_10_1016_j_vaccine_2024_05_052 elsevier_sciencedirect_doi_10_1016_j_vaccine_2024_05_052 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X24006200 elsevier_clinicalkey_doi_10_1016_j_vaccine_2024_05_052 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-17 |
| PublicationDateYYYYMMDD | 2024-09-17 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2024 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | September 6, 2023. Available at: http://www.bccdc.ca/resourcegallery/Documents/BC%20Provincial%20Pertussis%20Summary%20Final.pdf. Accessed on December 16, 2023. Guzman-Holst, Gomez, Cintra, Van Oorschot, Jamet, Nieto-Guevara (b0130) 2023 Watts, Mâsse, Goldfarb, Irvine, Hutchison, Muttucomaroe (b0060) 2023; 13 Macina, Evans (b0030) 2021; 10 Centers for Disease Control and Prevention. Available at Althouse, Scarpino (b0015) 2015; 13 Hodder, Cherry, Mortimer, Ford, Gornbein, Papp (b0085) 2000; 31 Guiso, Berbers, Fry, He, Riffelmann, Wirsing von König (b0070) 2011; 30 Craig, Kunkel, Crowcroft, Fitzpatrick, de Melker, Althouse (b0140) 2020; 70 Carbonetti (b0185) 2010; 5 Dalby (b0120) 2023 2023. Urbiztondo, Broner, Costa, Rocamora, Bayas, Campins (b0165) 2015; 11 Yun, Ryu, Choe (b0100) 2021; 93 Wehlin, Ljungman, Kühlmann-Berenzon, Galanis, Huygen, Pierard (b0170) 2021; 129 van Summeren, Meijer, Aspelund, Casalegno, Erna, Hoang (b0045) 2021; 26 Tessier, Campbell, Ribeiro, Rai, Burton, Roy (b0110) 2022; 22 Platt, Thun, Harriman, Winter (b0190) 2017; 65 McIntyre, Best, Byrnes, Sinclair, Trenholme, Grant (b0115) 2023; 37 Dubois, Chatagnon, Thiriard, Bauderlique-Le Roy, Debrie, Coutte (b0150) 2021; 6 Klein, Bartlett, Fireman, Baxter (b0010) 2016; 137 Reicherz, Xu, Abu-Raya, Majdoubi, Michalski, Golding (b0040) 2022; 226 BC centre for disease control. British Columbia Provincial Pertussis Summary. Witt, Katz, Witt (b0005) 2012; 54 World Health Organization. WHO Technical Report, Series No. 924, 2004. Annex 1. Guidelines on clinical evaluation of vaccines: regulatory expectations. Available at: https://cdn.who.int/media/docs/default-source/biologicals/vaccine-quality/guidelines-on-clinical-evaluation-of-vaccines-regulatory-expectations867c9e6a-f022-47e6-986e-235fbc274b0f.pdf?sfvrsn=40d99bd4_1&download=true . Accessed on April 14, 2024. . Saemann-Ischenko, Tillmanns, Kösters, Riffelmann, Wirsing von König (b0080) 2001; 20 Reicherz, Golding, Lavoie, Abu-Raya (b0050) 2022 INCREASE IN CASES OF PERTUSSIS . Risk Assessment Group. Available at: https://www.sciensano.be/sites/default/files/20231002_rag_pra_pertussis.pdf . Accessed on December 30 t . Mungall, Kim, Oh (b0155) 2021; 17 Ward, Cherry, Chang, Partridge, Keitel, Edwards (b0135) 2006; 43 Abu-Raya, Bettinger, Vanderkooi, Vaudry, Halperin, Sadarangani (b0020) 2020; 9 Choi, Kim, Park (b0160) 2018; 33 Warfel, Zimmerman, Merkel (b0145) 2014; 111 Hewlett, Edwards (b0025) 2005; 352 Chen Z, Pang J, Zhang Y, Ding Y, Chen N, Zhang N, et al. Seroprevalence of pertussis in adults at childbearing age pre- and post- COVID-19 in Beijing, China. Vaccines (Basel). 2022;10. Goldfarb, Mâsse, Watts, Hutchison, Muttucomaroe, Bosman (b0065) 2022; 12 Falkenstein-Hagander, Appelqvist, Cavefors, Källberg, Nilsson, Silfverdal (b0105) 2021 Huh, Jung, Hong, Kim, Ahn, Kim (b0095) 2021; 72 https://www.cdc.gov/vaccines/pubs/pinkbook/pert.html. Accessed on August 1st, 2023. Adegbija, Walker, Smoll, Khan, Graham, Khandaker (b0090) 2018; 2021 He, Zhu, Jin, Zhou, Tang, Yan (b0175) 2022; 40 Macina (10.1016/j.vaccine.2024.05.052_b0030) 2021; 10 Saemann-Ischenko (10.1016/j.vaccine.2024.05.052_b0080) 2001; 20 Yun (10.1016/j.vaccine.2024.05.052_b0100) 2021; 93 Falkenstein-Hagander (10.1016/j.vaccine.2024.05.052_b0105) 2021 Althouse (10.1016/j.vaccine.2024.05.052_b0015) 2015; 13 Carbonetti (10.1016/j.vaccine.2024.05.052_b0185) 2010; 5 Warfel (10.1016/j.vaccine.2024.05.052_b0145) 2014; 111 McIntyre (10.1016/j.vaccine.2024.05.052_b0115) 2023; 37 Abu-Raya (10.1016/j.vaccine.2024.05.052_b0020) 2020; 9 Dalby (10.1016/j.vaccine.2024.05.052_b0120) 2023 Tessier (10.1016/j.vaccine.2024.05.052_b0110) 2022; 22 Goldfarb (10.1016/j.vaccine.2024.05.052_b0065) 2022; 12 Reicherz (10.1016/j.vaccine.2024.05.052_b0050) 2022 10.1016/j.vaccine.2024.05.052_b0180 Wehlin (10.1016/j.vaccine.2024.05.052_b0170) 2021; 129 Watts (10.1016/j.vaccine.2024.05.052_b0060) 2023; 13 Guiso (10.1016/j.vaccine.2024.05.052_b0070) 2011; 30 Platt (10.1016/j.vaccine.2024.05.052_b0190) 2017; 65 Klein (10.1016/j.vaccine.2024.05.052_b0010) 2016; 137 He (10.1016/j.vaccine.2024.05.052_b0175) 2022; 40 Choi (10.1016/j.vaccine.2024.05.052_b0160) 2018; 33 van Summeren (10.1016/j.vaccine.2024.05.052_b0045) 2021; 26 10.1016/j.vaccine.2024.05.052_b0125 Guzman-Holst (10.1016/j.vaccine.2024.05.052_b0130) 2023 Huh (10.1016/j.vaccine.2024.05.052_b0095) 2021; 72 Dubois (10.1016/j.vaccine.2024.05.052_b0150) 2021; 6 Urbiztondo (10.1016/j.vaccine.2024.05.052_b0165) 2015; 11 Craig (10.1016/j.vaccine.2024.05.052_b0140) 2020; 70 10.1016/j.vaccine.2024.05.052_b0075 Hewlett (10.1016/j.vaccine.2024.05.052_b0025) 2005; 352 10.1016/j.vaccine.2024.05.052_b0055 Hodder (10.1016/j.vaccine.2024.05.052_b0085) 2000; 31 10.1016/j.vaccine.2024.05.052_b0035 Ward (10.1016/j.vaccine.2024.05.052_b0135) 2006; 43 Adegbija (10.1016/j.vaccine.2024.05.052_b0090) 2018; 2021 Reicherz (10.1016/j.vaccine.2024.05.052_b0040) 2022; 226 Witt (10.1016/j.vaccine.2024.05.052_b0005) 2012; 54 Mungall (10.1016/j.vaccine.2024.05.052_b0155) 2021; 17 |
| References_xml | – reference: September 6, 2023. Available at: http://www.bccdc.ca/resourcegallery/Documents/BC%20Provincial%20Pertussis%20Summary%20Final.pdf. Accessed on December 16, 2023. – volume: 72 start-page: e184 year: 2021 end-page: e191 ident: b0095 article-title: Impact of nonpharmaceutical interventions on the incidence of respiratory infections during the coronavirus disease 2019 (COVID-19) outbreak in Korea: A nationwide surveillance study publication-title: Clin Infect Dis – volume: 352 start-page: 1215 year: 2005 end-page: 1222 ident: b0025 article-title: Clinical practice. Pertussis–not just for kids publication-title: N Engl J Med – volume: 40 start-page: 6956 year: 2022 end-page: 6962 ident: b0175 article-title: The decline in immunity and circulation of pertussis among Chinese population during the COVID-19 pandemic: A cross-sectional sero-epidemiological study publication-title: Vaccine – volume: 30 start-page: 307 year: 2011 end-page: 312 ident: b0070 article-title: What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories publication-title: Eur J Clin Microbiol Infect Dis – reference: World Health Organization. WHO Technical Report, Series No. 924, 2004. Annex 1. Guidelines on clinical evaluation of vaccines: regulatory expectations. Available at: https://cdn.who.int/media/docs/default-source/biologicals/vaccine-quality/guidelines-on-clinical-evaluation-of-vaccines-regulatory-expectations867c9e6a-f022-47e6-986e-235fbc274b0f.pdf?sfvrsn=40d99bd4_1&download=true . Accessed on April 14, 2024. . – volume: 137 start-page: e20153326 year: 2016 ident: b0010 article-title: Waning Tdap effectiveness in adolescents publication-title: Pediatrics – year: 2021 ident: b0105 article-title: Waning infant pertussis during COVID-19 pandemic publication-title: Arch Dis Child – year: 2023 ident: b0120 article-title: Clarifying pertussis in Denmark publication-title: Lancet Infect Dis – volume: 6 start-page: 6 year: 2021 ident: b0150 article-title: Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage publication-title: NPJ Vaccines – volume: 13 start-page: e071228 year: 2023 ident: b0060 article-title: SARS-CoV-2 cross-sectional seroprevalence study among public school staff in Metro Vancouver after the first Omicron wave in British Columbia publication-title: Canada BMJ Open – volume: 12 start-page: e057846 year: 2022 ident: b0065 article-title: SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study publication-title: BMJ Open – volume: 22 start-page: 405 year: 2022 ident: b0110 article-title: Impact of the COVID-19 pandemic on Bordetella pertussis infections in England publication-title: BMC Public Health – volume: 10 start-page: 719 year: 2021 end-page: 738 ident: b0030 article-title: Bordetella pertussis in school-age children, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in the middle east publication-title: Infect Dis Ther – volume: 17 start-page: 1747 year: 2021 end-page: 1756 ident: b0155 article-title: A systematic review of the burden of pertussis in South Korea publication-title: Hum Vaccin Immunother – volume: 31 start-page: 7 year: 2000 end-page: 14 ident: b0085 article-title: Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents publication-title: Clin Infect Dis – reference: , 2023. – volume: 33 start-page: e321 year: 2018 ident: b0160 article-title: Seroprevalence of pertussis in healthcare workers without adult pertussis vaccine use at a university hospital in Korea publication-title: J Korean Med Sci – volume: 93 start-page: 1814 year: 2021 end-page: 1816 ident: b0100 article-title: Impact of social distancing on incidence of vaccine-preventable diseases publication-title: South Korea J Med Virol – volume: 129 start-page: 556 year: 2021 end-page: 565 ident: b0170 article-title: Pertussis seroprevalence among adults of reproductive age (20–39 years) in fourteen European countries publication-title: APMIS – volume: 2021 start-page: 45 year: 2018 ident: b0090 article-title: Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland publication-title: Australia Commun Dis Intell – volume: 70 start-page: 152 year: 2020 end-page: 161 ident: b0140 article-title: Asymptomatic Infection and Transmission of Pertussis in Households: A Systematic Review publication-title: Clin Infect Dis – volume: 5 start-page: 455 year: 2010 end-page: 469 ident: b0185 article-title: Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools publication-title: Future Microbiol – volume: 13 start-page: 146 year: 2015 ident: b0015 article-title: Asymptomatic transmission and the resurgence of Bordetella pertussis publication-title: BMC Med – reference: Centers for Disease Control and Prevention. Available at: – reference: https://www.cdc.gov/vaccines/pubs/pinkbook/pert.html. Accessed on August 1st, 2023. – volume: 37 year: 2023 ident: b0115 article-title: Pertussis deaths in New Zealand without community transmission-an infant immunity gap? publication-title: Lancet Reg Health West Pac – year: 2022 ident: b0050 article-title: Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measures publication-title: Vaccine – reference: INCREASE IN CASES OF PERTUSSIS . Risk Assessment Group. Available at: https://www.sciensano.be/sites/default/files/20231002_rag_pra_pertussis.pdf . Accessed on December 30 t – volume: 111 start-page: 787 year: 2014 end-page: 792 ident: b0145 article-title: Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model publication-title: Proc Natl Acad Sci U S A – volume: 9 start-page: 118 year: 2020 end-page: 127 ident: b0020 article-title: Burden of children hospitalized with pertussis in Canada in the acellular pertussis vaccine era, 1999–2015 publication-title: J Pediatric Infect Dis Soc – volume: 226 start-page: 2064 year: 2022 end-page: 2068 ident: b0040 article-title: Waning immunity against respiratory syncytial virus during the coronavirus disease 2019 pandemic publication-title: J Infect Dis – volume: 11 start-page: 293 year: 2015 end-page: 297 ident: b0165 article-title: Seroprevalence study of B. pertussis infection in health care workers in Catalonia, Spain publication-title: Hum Vaccin Immunother – reference: BC centre for disease control. British Columbia Provincial Pertussis Summary. – volume: 43 start-page: 151 year: 2006 end-page: 157 ident: b0135 article-title: Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT) publication-title: Clin Infect Dis – reference: Chen Z, Pang J, Zhang Y, Ding Y, Chen N, Zhang N, et al. Seroprevalence of pertussis in adults at childbearing age pre- and post- COVID-19 in Beijing, China. Vaccines (Basel). 2022;10. – reference: . – volume: 54 start-page: 1730 year: 2012 end-page: 1735 ident: b0005 article-title: Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak publication-title: Clin Infect Dis – volume: 20 start-page: 850 year: 2001 end-page: 853 ident: b0080 article-title: Stability of antibodies to Bordetella antigens in German adults publication-title: Eur J Clin Microbiol Infect Dis – year: 2023 ident: b0130 article-title: Assessing the underestimation of adult pertussis disease in five latin American countries publication-title: Infect Dis Ther – volume: 65 start-page: 2099 year: 2017 end-page: 2104 ident: b0190 article-title: A population-based study of recurrent symptomatic bordetella pertussis infections in children in California, 2010–2015 publication-title: Clin Infect Dis – volume: 26 year: 2021 ident: b0045 article-title: Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? publication-title: Euro Surveill – volume: 13 start-page: 146 year: 2015 ident: 10.1016/j.vaccine.2024.05.052_b0015 article-title: Asymptomatic transmission and the resurgence of Bordetella pertussis publication-title: BMC Med doi: 10.1186/s12916-015-0382-8 – volume: 2021 start-page: 45 year: 2018 ident: 10.1016/j.vaccine.2024.05.052_b0090 article-title: Notifiable diseases after implementation of COVID-19 public health prevention measures in Central Queensland publication-title: Australia Commun Dis Intell – volume: 22 start-page: 405 year: 2022 ident: 10.1016/j.vaccine.2024.05.052_b0110 article-title: Impact of the COVID-19 pandemic on Bordetella pertussis infections in England publication-title: BMC Public Health doi: 10.1186/s12889-022-12830-9 – volume: 43 start-page: 151 year: 2006 ident: 10.1016/j.vaccine.2024.05.052_b0135 article-title: Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT) publication-title: Clin Infect Dis doi: 10.1086/504803 – volume: 70 start-page: 152 year: 2020 ident: 10.1016/j.vaccine.2024.05.052_b0140 article-title: Asymptomatic Infection and Transmission of Pertussis in Households: A Systematic Review publication-title: Clin Infect Dis doi: 10.1093/cid/ciz531 – volume: 12 start-page: e057846 year: 2022 ident: 10.1016/j.vaccine.2024.05.052_b0065 article-title: SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study publication-title: BMJ Open doi: 10.1136/bmjopen-2021-057846 – year: 2022 ident: 10.1016/j.vaccine.2024.05.052_b0050 article-title: Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measures publication-title: Vaccine doi: 10.1016/j.vaccine.2022.04.086 – ident: 10.1016/j.vaccine.2024.05.052_b0075 – volume: 17 start-page: 1747 year: 2021 ident: 10.1016/j.vaccine.2024.05.052_b0155 article-title: A systematic review of the burden of pertussis in South Korea publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2020.1844505 – volume: 40 start-page: 6956 year: 2022 ident: 10.1016/j.vaccine.2024.05.052_b0175 article-title: The decline in immunity and circulation of pertussis among Chinese population during the COVID-19 pandemic: A cross-sectional sero-epidemiological study publication-title: Vaccine doi: 10.1016/j.vaccine.2022.10.020 – volume: 6 start-page: 6 year: 2021 ident: 10.1016/j.vaccine.2024.05.052_b0150 article-title: Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal Bordetella pertussis carriage publication-title: NPJ Vaccines doi: 10.1038/s41541-020-00270-8 – ident: 10.1016/j.vaccine.2024.05.052_b0035 – year: 2023 ident: 10.1016/j.vaccine.2024.05.052_b0120 article-title: Clarifying pertussis in Denmark publication-title: Lancet Infect Dis – volume: 10 start-page: 719 year: 2021 ident: 10.1016/j.vaccine.2024.05.052_b0030 article-title: Bordetella pertussis in school-age children, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in the middle east publication-title: Infect Dis Ther doi: 10.1007/s40121-021-00440-8 – volume: 31 start-page: 7 year: 2000 ident: 10.1016/j.vaccine.2024.05.052_b0085 article-title: Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents publication-title: Clin Infect Dis doi: 10.1086/313913 – volume: 33 start-page: e321 year: 2018 ident: 10.1016/j.vaccine.2024.05.052_b0160 article-title: Seroprevalence of pertussis in healthcare workers without adult pertussis vaccine use at a university hospital in Korea publication-title: J Korean Med Sci doi: 10.3346/jkms.2018.33.e321 – volume: 26 year: 2021 ident: 10.1016/j.vaccine.2024.05.052_b0045 article-title: Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2021.26.29.2100639 – volume: 137 start-page: e20153326 year: 2016 ident: 10.1016/j.vaccine.2024.05.052_b0010 article-title: Waning Tdap effectiveness in adolescents publication-title: Pediatrics doi: 10.1542/peds.2015-3326 – volume: 226 start-page: 2064 year: 2022 ident: 10.1016/j.vaccine.2024.05.052_b0040 article-title: Waning immunity against respiratory syncytial virus during the coronavirus disease 2019 pandemic publication-title: J Infect Dis doi: 10.1093/infdis/jiac192 – ident: 10.1016/j.vaccine.2024.05.052_b0180 doi: 10.3390/vaccines10060872 – volume: 9 start-page: 118 year: 2020 ident: 10.1016/j.vaccine.2024.05.052_b0020 article-title: Burden of children hospitalized with pertussis in Canada in the acellular pertussis vaccine era, 1999–2015 publication-title: J Pediatric Infect Dis Soc doi: 10.1093/jpids/piy128 – volume: 93 start-page: 1814 year: 2021 ident: 10.1016/j.vaccine.2024.05.052_b0100 article-title: Impact of social distancing on incidence of vaccine-preventable diseases publication-title: South Korea J Med Virol doi: 10.1002/jmv.26614 – volume: 129 start-page: 556 year: 2021 ident: 10.1016/j.vaccine.2024.05.052_b0170 article-title: Pertussis seroprevalence among adults of reproductive age (20–39 years) in fourteen European countries publication-title: APMIS doi: 10.1111/apm.13165 – volume: 20 start-page: 850 year: 2001 ident: 10.1016/j.vaccine.2024.05.052_b0080 article-title: Stability of antibodies to Bordetella antigens in German adults publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-001-0639-3 – volume: 5 start-page: 455 year: 2010 ident: 10.1016/j.vaccine.2024.05.052_b0185 article-title: Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools publication-title: Future Microbiol doi: 10.2217/fmb.09.133 – volume: 13 start-page: e071228 year: 2023 ident: 10.1016/j.vaccine.2024.05.052_b0060 article-title: SARS-CoV-2 cross-sectional seroprevalence study among public school staff in Metro Vancouver after the first Omicron wave in British Columbia publication-title: Canada BMJ Open doi: 10.1136/bmjopen-2022-071228 – ident: 10.1016/j.vaccine.2024.05.052_b0055 – volume: 30 start-page: 307 year: 2011 ident: 10.1016/j.vaccine.2024.05.052_b0070 article-title: What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-010-1104-y – volume: 11 start-page: 293 year: 2015 ident: 10.1016/j.vaccine.2024.05.052_b0165 article-title: Seroprevalence study of B. pertussis infection in health care workers in Catalonia, Spain publication-title: Hum Vaccin Immunother doi: 10.4161/hv.36167 – volume: 65 start-page: 2099 year: 2017 ident: 10.1016/j.vaccine.2024.05.052_b0190 article-title: A population-based study of recurrent symptomatic bordetella pertussis infections in children in California, 2010–2015 publication-title: Clin Infect Dis doi: 10.1093/cid/cix691 – volume: 352 start-page: 1215 year: 2005 ident: 10.1016/j.vaccine.2024.05.052_b0025 article-title: Clinical practice. Pertussis–not just for kids publication-title: N Engl J Med doi: 10.1056/NEJMcp041025 – volume: 54 start-page: 1730 year: 2012 ident: 10.1016/j.vaccine.2024.05.052_b0005 article-title: Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak publication-title: Clin Infect Dis doi: 10.1093/cid/cis287 – ident: 10.1016/j.vaccine.2024.05.052_b0125 – volume: 37 year: 2023 ident: 10.1016/j.vaccine.2024.05.052_b0115 article-title: Pertussis deaths in New Zealand without community transmission-an infant immunity gap? publication-title: Lancet Reg Health West Pac – year: 2021 ident: 10.1016/j.vaccine.2024.05.052_b0105 article-title: Waning infant pertussis during COVID-19 pandemic publication-title: Arch Dis Child – volume: 72 start-page: e184 year: 2021 ident: 10.1016/j.vaccine.2024.05.052_b0095 article-title: Impact of nonpharmaceutical interventions on the incidence of respiratory infections during the coronavirus disease 2019 (COVID-19) outbreak in Korea: A nationwide surveillance study publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa1682 – year: 2023 ident: 10.1016/j.vaccine.2024.05.052_b0130 article-title: Assessing the underestimation of adult pertussis disease in five latin American countries publication-title: Infect Dis Ther doi: 10.1007/s40121-023-00895-x – volume: 111 start-page: 787 year: 2014 ident: 10.1016/j.vaccine.2024.05.052_b0145 article-title: Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1314688110 |
| SSID | ssj0005319 |
| Score | 2.4484484 |
| Snippet | We recently reported a near disappearance of B. pertussis and a decline in anti-B. pertussis antibodies during the peak implementation of Coronavirus disease... AbstractBackgroundWe recently reported a near disappearance of B. pertussis and a decline in anti- B. pertussis antibodies during the peak implementation of... Background We recently reported a near disappearance of B. pertussis and a decline in anti- B. pertussis antibodies during the peak implementation of... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 126004 |
| SubjectTerms | Adult Allergy and Immunology Antibodies, Bacterial - blood blood Bordetella pertussis Bordetella pertussis - immunology British Columbia British Columbia - epidemiology confidence interval Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - immunology COVID-19 - prevention & control COVID-19 infection COVID-19 vaccines Criteria Diphtheria Disease transmission Female Humans Immunoglobulin G Immunoglobulin G - blood Infections Male Metropolitan areas Middle Aged Pandemics Personal protective equipment Pertussis Pertussis toxin Pertussis Toxin - immunology Pharmaceuticals Population studies Samples SARS-CoV-2 - immunology Sensitivity analysis Seroconversion Serology Statistical analysis Tetanus Toxins Vaccination vaccines Viral diseases Whooping cough Whooping Cough - immunology Whooping Cough - prevention & control |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELagCNQLguUvUJCRUE-bNnZ-nJwQLFQFqVCJdpWbZcex2Eok2yYL9MY78BI8F0_CjJNseqAFaS-7G6-zmfHMN_bMN4S8YInlsRHCFyaFACVTzNeGKd8arkUUW2sEFgoffEj2j6P3eZz3G25Nn1Y52ERnqE1d4B75bghQhoN2CfZyeepj1yg8Xe1baFwnNxx1GeizyMWY4hG6xh4QZkR-xIJ8rODZPdn5qgo8uoYQkUeOvDPml_mmy7Cn80F7d8jtHjzSV52075JrZTUhN7t2kucTcuugPyifkO3DjpL6fEqPxgqrZkq36eFIVg1jJnPMh3FFuXQYfo_8eo2UnFhgouiyPGtXsHIaOiRuVdSC9tTfwOtRrIX57qRLa0tnH-fv3vgso1Vd-cvPF7fL6eJCdiX-FoVHwn7_-Imd1fHtHPSvXsHKol_K1vVuWABwpQpQ7ZT23Et0hsZUL-ATR6ug7pPjvbdHs32_7-ngF1Eatn5RpkGcamG5TazmWKYbG6sMNj1JUgNokCtdpKkOkSYmiwpTIH1BpBGqCcbCB2QD_kL5iNBAsSLUIgtUDDGkTrQpQxsnRao0w0k8sjNIUy476g455LSdyF78EsUvgxhe3CPJIHM51KWCJZXgXP41UPxtYNn09qCRTDZcBvJT4PBnkGPmbgIGyiPpemQPeToo8z-Tbg1qKdfzjKvEI8_XX4PFwGMgVZX1Cq9JACdics4V14AjhLiLi8wjDzuVXz_DMBWAYbl4fPUNPCGbeLeYW8PEFtloz1blUwBwrX7mVukfE-9GHA priority: 102 providerName: ProQuest |
| Title | Bordetella pertussis infection following relaxation of COVID-19 non-pharmaceutical interventions in 2021–2023 in Vancouver metropolitan area, British Columbia, Canada |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X24006200 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X24006200 https://dx.doi.org/10.1016/j.vaccine.2024.05.052 https://www.ncbi.nlm.nih.gov/pubmed/38797627 https://www.proquest.com/docview/3099278771 https://www.proquest.com/docview/3060752002 https://www.proquest.com/docview/3153772279 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbhMxEB61qUBcEAQogYKMhHrKNmvvj73HNrRKQQ0RtFFulr27FqlEEjUJ0AviHXgJnosnYWZ_kiIoIKRos7vxxBvPeOZzPD8Az3nsRJRJ6clM4QIlMdyzGTeey4SVYeRcJilQ-KQf987Cl6NotAHdOhaG3Cor3V_q9EJbV3c61Wh2ZuNx561f2HJ_RF6QMTJ7E7ZEkMRRA7b2j1_1-mtPj6Co70HtPSJYB_J0zvc-mJR2sHGlKMIih2ckrjNR10HQwhQd3YHbFYZk--Vj3oWNfNKEG2VVycsm3Dyp9subsDsoM1NfttnpOtBq3ma7bLDOWY00zSG5xRSxuawmvwffDigzJ8WZGDbLLxZLnEBzVvtvTZhDIZp-ROPHKCTmU8FkNnWs-3p4_MLjCZtMJ97s3dV_zdn4ipMlfRfDIeHfv3ylAut0OUQxnC5xgrH3-aIo4TBG_MoMgts2q1IwsS7pVDvGO0V2BXMfzo4OT7s9ryrt4KWhChZemis_UlY64WJnBUXrRpkzGdU-iVWGoFAYmyplA8oWk4RpllIWg9ASYpOcBw-ggT8hfwjMNzwNrEx8E-FS0sY2ywMXxakyllMnLdirualnZQYPXbu2neuK_ZrYr_0IX6IFcc1zXYenokLVaGP-Rih_R5jPK7Uw11zPhfb1L6LbArWi_En6_6XTnVos9aqfAHG_QFUseQuerT5GxUG7QWaST5fUJka4SD46f2iD9hCXX0ImLdguRX41hoGSCGWFfPT_z_4YbtEVud9wuQONxcUyf4IYb2GfwubeZ45HOZJ4VF08L2c1vh8c9gdvfgCI9FXE |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVDwuCAKFQIFFgp7i1rt-rHNAiKatEtqECNIot2XXD5FKJKFOKLnxH_gTnPhR_BJm_Eh6oIVLpVwSe72OZ3bmG-98MwAvuJ8IL5LSklGAAUpDc8tEXFtJJIx0vSSJJBGFO12_dey-HXrDNfhVcmEorbK0iZmhjiYhvSPfcRDKCNQuyV9Pv1jUNYp2V8sWGrlaHMaLMwzZ0lftPZTvSyEO9vvNllV0FbBCN3BmVhgHthcYmYjET4wgoqgXJTqitht-ECEeEdqEQWAcKlTScMMoJAK9awgsSM4dvO41WHeJ0VqB9d39bu_9KqnEyVqJYGDjWi63hyvO0M7J9lcd0mY5BqXCzcqFeuIib3gR2s283sEduF3AVfYm16-7sBaPq3A9b2C5qMKNTrE1X4WtXl4Ee1Fn_RWnK62zLdZblcfGMdUBZeBkNGBWDr8HP3epCChRWjSbxqezOa7VlJWpYmOWoL5OztDPMmLffMv0iU0S1nw3aO9ZvMHGk7E1_XT-BT0bncvnpGsxfCT89_cf1Mudvg5Q4ydzXMvsczzLukWMECozjTi6zopqT6xJ5tuM8JeskIO-D8dXIu8NqOBfiB8CszUPHSMbtvYwajW-iWIn8fww0IbTJDXYLqWppnmxEFVm0Z2oQvyKxK9sDz-iBn4pc1UyYdF2K3Rn_xoo_zYwTgsLlCquUqFs9cHOEK89pFxhH01iDYLlyAJk5eDpfybdLNVSLedZrcsaPF8eRhtFG096HE_mdI6PyJTSgS45B10vRnpCNmrwIFf55TN0AomoWchHl9_AM7jZ6neO1FG7e_gYbtGdU2YPl5tQmZ3O4ycIH2fmabFmGXy8ajPxBx9sg4M |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIiouCMIrUGCRoKe48a4f6xwQgoSopbREoo1yW3Ztr0gl4lAnlNz4D_wJfgM_h1_CjB9JD7RwqZRLYo_X8by-8c4D4BkPrQgSKR2ZRBigdDR3TMK1YxNhpB9Ym0gqFN4_CHeO_LejYLQGv-paGEqrrG1iYaiTLKZ35G0PoYxA6ZK8bau0iEGv_3L6xaEJUrTTWo_TKEVkL12cYviWv9jtIa-fC9F_c9jdcaoJA07sR97MidPIDSIjrbChNYKKRoPE6oRGcIRRgthEaBNHkfGoaUnHj5OYiul9Q8BBcu7hda_AVekhqkJdkiO5Si_xiqEiGOL4js_d0ap6qH28_VXHtG2O4anwi8ahgTjPL56Hewv_178JNyrgyl6VknYL1tJJA66VoywXDdjYrzbpG7A1KNthL1rscFXdlbfYFhusGmUjTWNIuThFQTCryW_Dz9fUDpSKWzSbpiezOWptzuqksQmzKLnZKXpcRnU43wrJYpll3ffD3Z7DO2ySTZzpp7Ov6tn4TGYnXYvhI-G_v_-gqe70dYiyn81Rq9nndFbMjRgjaGYaEXWLVX2fWJcMuRnjL0VLB30Hji6F23dhHf9Ceh-Yq3nsGdlxdYDxqwlNkno2CONIG06LNGG75qaalm1DVJ1Pd6wq9itiv3ID_IgmhDXPVV0Ti1ZcoWP7F6H8G2GaV7YoV1zlQrnqg1tgX3dEWcMhGscmREvKCm6VMOp_Ft2sxVIt11lpaBOeLg-jtaItKD1JszmdEyJGpcSgC85BJ4wxn5CdJtwrRX75DL1IIn4W8sHFN_AENtA4qHe7B3sP4TrdOKX4cLkJ67OTefoIceTMPC4UlsHHy7YQfwCV-IZK |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bordetella+pertussis+infection+following+relaxation+of+COVID-19+non-pharmaceutical+interventions+in+2021%E2%80%932023+in+Vancouver+metropolitan+area%2C+British+Columbia%2C+Canada&rft.jtitle=Vaccine&rft.au=Reicherz%2C+Frederic&rft.au=Li%2C+Sirui&rft.au=Watts%2C+Allison+A.&rft.au=Goldfarb%2C+David+M.&rft.date=2024-09-17&rft.issn=0264-410X&rft.volume=42&rft.issue=22+p.126004-&rft_id=info:doi/10.1016%2Fj.vaccine.2024.05.052&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X24X00249%2Fcov150h.gif |